The escalating popularity of weight loss medications and the subsequent inquiries from employees have positioned employers in the United States at a challenging crossroad. An annual report by Pharmaceutical Strategies Group (PSG) reveals that employers’ decisions on whether to cover the costs of these expensive medications vary, shedding light on a potentially shifting landscape of employee healthcare benefits.
The PSG report, which surveyed over 150 employers and health plans, shows that 43% of employers currently cover FDA-approved weight loss medications, while a further 28% are considering adding such coverage within the next couple of years. A noteworthy observation from the report is the roughly equal proportion of smaller and larger employers currently covering these medications (42% and 40%, respectively). However, a noticeable disparity arises when considering future plans, with larger employers (36%) more likely to be considering coverage compared to their smaller counterparts (20%).
In spite of obesity being recognized as a disease by the American Medical Association in 2013, employers remain divided. According to the PSG report, some view it as a lifestyle condition that should not be covered (24%), while others see it as a chronic condition that merits treatment (21%). The foremost reason employers decide not to cover FDA-approved weight loss drugs is the perception of these medications as lifestyle drugs. Other reservations include high costs often exceeding $10,000 per individual annually, skepticism regarding long-term weight loss effects, and the indefinite duration of medication.
Regarding employers who do cover FDA-approved weight loss drugs, some conditions often apply. The report revealed that 22% of such employers require employees to participate in a lifestyle modification program to qualify for the drugs, and for another 20%, participation in such programs is voluntary. Interestingly, only a small fraction (16%) currently measures the outcomes of these drugs. However, there are plans for the implementation of such measures among 36% of these employers. Despite being allowed to impose restrictions on weight loss medications coverage, such as cost or duration of treatment limits, only 14% have elected to do so.
Employer Takeaway
Understanding these emerging trends can significantly aid employers in making informed decisions regarding their organizations and benefits plans. As the demand for weight loss drugs increases, employers find themselves having to navigate the tricky path of whether or not to cover these medications.
Concluding Thoughts
While an increasing number of employers are recognizing the desire and need for FDA-approved weight loss medications among their employees, the decision to cover the costs is multifaceted, involving not only financial implications but also philosophical debates about healthcare responsibility. The PSG report highlights the current state of affairs, offering insights for employers to consider.
The inclusion of weight loss medications in health plans could be a progressive step towards prioritizing employees’ health and well-being. However, such a move must be weighed against financial implications and effectiveness. It is equally important to establish rigorous metrics to measure outcomes and the long-term benefits of such medications. This will ensure not only the optimal utilization of resources but also the alignment of these benefits with the holistic health goals of employees.
